Marico raises Plix stake to 84% for ₹1,012 crore

Marico acquired an additional 24.09% stake in Satiya Nutraceuticals for ₹1,012.03 crore, raising its total holding to 84.09%. This secures deeper control over the high-growth digital wellness brand Plix ahead of a planned full buyout by July 2027. The transaction follows Satiya's FY26 turnover doubling to ₹864.31 crore from ₹432.84 crore in FY25. This matters because it accelerates Marico's pivot from low-margin commodity staples to high-growth, digital-first plant-based nutrition. I am watching the Q3 FY27 consolidated earnings for Plix's specific EBITDA margin contribution and the execution timeline for the final ₹592 crore tranche. The market is pricing this ₹1,012 crore outlay purely as expensive capital deployment, fixated on the premium valuation multiple. What the consensus misses is the structural multiple re-rating this enables for Marico's overall portfolio. Traditional FMCG staples trade at compressed multiples due to volume stagnation and input cost volatility. By consolidating a brand that nearly doubled its revenue in a year, Marico is actively injecting a high-velocity, digital-first growth engine into its core. My analysis shows that absorbing Plix's superior gross margins will mechanically lift the parent's blended EBITDA profile over the next four quarters. The market treats this as a standard FMCG acquisition, ignoring that it is a strategic arbitrage play to transition Marico's valuation from a legacy staple proxy to a premium wellness conglomerate. Accumulate for long-term portfolio premiumization. Disclosure: I do not hold positions in this stock. This is for educational purposes only and does not constitute investment advice.